Tevogen Bio, a clinical stage biotechnology company specializing in developing cell and gene therapies in oncology and viral infections, opened of its new corporate office at 15 Independence Boulevard, Warren.
The facility, located in New Jersey’s biotech corridor, will serve as the company’s central location for corporate operations and was selected after thorough countrywide market research. Proximity to biopharma service providers in the area, a mature medical innovation ecosystem and access to the specialized talent pool within commutable distance from this location will support the company’s expected rapid expansion in cell and gene therapy business, according to Tevogen CEO Ryan Saadi, M.D., M.P.H..
“Our corporate hub represents an important operational next step to best strategically support the diversification and expansion of our portfolio of T cell immunotherapies,” Saadi said. Within 18 months of inception, the company has invented and secured several US patents, moved its lead product from discovery to clinical trial, and achieved manufacturing readiness. “This rapid progress directly contributed to cost efficiency and is a testament to the business prudence of our leadership. We believe this agile, cost-efficient and population centric business model along with disruptive science are critical to succeed in the post pandemic world,” Saadi added.
Tevogen’s off-the-shelf allogeneic T cell technology overcomes the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing. Tevogen’s current intellectual property portfolio includes several disruptive cell and gene therapy platforms, which are internally invented and solely owned by the company. These breakthrough innovations open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.
The company’s lead product, TVGN-489 is currently in clinical trials for high-risk patients at Jefferson University Hospitals in Philadelphia. Tevogen recently announced it has completed dosing of the second cohort of patients in the proof-of- concept clinical trial of TVGN-489, marking the midway point of the trial’s planned four dosing levels. Trial details and recruitment information are available at Clinical Trials – Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, which is designed to detect targets spread across the entire viral genome. These targeted CTLs are designed to recognize and kill off virally infected cells, hopefully allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.
The company also recently announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes.
To access more business news, visit NJB News Now.Related Articles: